BCTXF

Briacell Therapeutics Corp.

 
Ordinary Shares International Reporting
OTCQB
Verified Company Profile 7/26/2016
Contact Info
  • 820 Heinz Avenue
  • Berkeley, CA 94710

Business Description


 
Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Apr 30, 2016 Quarterly Report
CIK 0001610820
Fiscal Year End 7/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o
Incorporated In: British Columbia, Canada
Year of Inc. 2006
Employees 12 a/o May 06, 2015
Company Officers/Contacts
William V. Williams, MD CEO
Gadi Levin CFO
Farrah Dean VP, Corp. Dev.
Company Directors
Dr. Saeid Babaei Chairman
William V. Williams, MD
Martin Schmieg
Rahoul Sharan
Dr. Charles Wiseman
Company Notes
  • Formerly=Ansell Capital Corp. until 12-2014
Service Providers
Accounting/Auditing Firm
MNP LLP
900- 50 Burnhamthorpe Road West
Sussex Centre
Mississauga, ONT, L5B3C2
Canada

Legal Counsel
Bennett Jones LLP
3400 One First Canadian Place
Toronto, ONT, M5X 1A4
Canada

Szaferman Lakind Blumstein & Blader, PC
101 Grovers Mill Road
2nd Floor
Lawrenceville, NJ, 08648
United States

Investor Relations Firm
Not Available
BCTXF Security Details
Share Structure
Market Value1 $10,592,039 a/o Dec 02, 2016
Authorized Shares Unlimited a/o Jun 15, 2015
Outstanding Shares 84,736,315 a/o Jun 15, 2015
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 63,145,299 a/o Apr 01, 2015
Par Value No Par Value
Shareholders
Shareholders of Record 33 a/o Jun 15, 2015
Non US Stock Exchange Listing
BCT - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 12,756 (-22.81%)
Nov 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security